The Zhitong Finance App learned that China Merchants Securities International released a research report stating that for the first time, Hebo Pharmaceutical (02142) was given an “increase in holdings” rating, with a target price of HK$28. The bank estimated the company's valuation of approximately US$3.1 billion, or HK$24.3 billion, through risk-adjusted net present value (RnPV).

The bank pointed out that it cooperated with Platinum Pharmaceuticals and the AI base model company Baitu Biotech to launch an industry-leading dry and wet integrated protein discovery platform to enable the development of complex protein macromolecule drugs using AI. The bank believes that Heplatinum Pharmaceuticals has strong fundamentals, rich pipeline assets and cash value in hand are extremely undervalued by the market, improving liquidity and providing sufficient safety cushion for the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.